Compare W W Grainger Inc (GWW) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs Recursion Pharmaceuticals Inc — how do they compare? W W Grainger Inc trades at $1,400.22 (market cap $64.75B), while Recursion Pharmaceuticals Inc trades at $3.03 (market cap $1.75B). The key difference: W W Grainger Inc is far larger — about 37× Recursion Pharmaceuticals Inc's market cap, and W W Grainger Inc pays a 0.68% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GWW | RXRX | |
|---|---|---|
Market Cap | $64.75B | $1.75B |
Sector | Technology | Health |
52-Week High | $1.39K | $6.79 |
52-Week Low | $918.18 | $2.84 |
Enterprise Value | $66.84B | $1.17B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GWW trades at $1,391.07, up 1.46% with strong technical momentum and bullish moving averages. The company reported solid Q1 2026 earnings of $11.65 per share, beating estimates, and raised full-year guidance. With revenue growth to $18.4B and net profit margin improving to 9.69%, fundamentals remain robust despite elevated valuation multiples.
Outlook remains positive with analyst consensus price target of $1,260 offering modest upside. Key risks include high P/E ratio of 36.88 and competitive pressures in industrial distribution. The stock presents a quality growth opportunity but requires monitoring of valuation sustainability amid economic uncertainties.
Recursion Pharmaceuticals (RXRX) trades at $3.07, down 8.08% in the last session, reflecting ongoing investor concerns about its financial performance. The stock shows a bearish technical signal with moving averages indicating selling pressure, while the company continues to report significant losses with a net income margin of -851.51% for 2025. Recent earnings have consistently beaten expectations, and analyst sentiment remains mixed with a consensus price target of $7.83 representing substantial upside potential from current levels.
The outlook for RXRX hinges on its ability to translate its AI-driven drug discovery platform into sustainable revenue growth and eventual profitability. While the company maintains analyst support and strong institutional backing, significant execution risks remain given its substantial cash burn and negative profitability metrics. The stock presents a high-risk, high-reward opportunity for investors willing to bet on the company's long-term technology potential despite current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
